



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

28 Sep 2020 (#43)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

- 

## Upcoming Deadlines

- [Harnessing Data Science for Health Discovery and Innovation in Africa \(DS-I Africa\)](#):  
Research Training Program due date: 24 November 2020  
Ethical, Legal, and Social Implications Research due date: 1 December 2020  
Open Data Science Platform and Coordinating Center due date: 3 December 2020  
Research Hubs non-AIDS application due date: 8 December 2020  
Research Hubs AIDS application due date: 8 February 2021
- [Mobile Health: Technology and Outcomes in LMICs](#) AIDS deadline 3 December 2020
- [Emerging Global Leader Award](#) 4 November 2020
- [Global Brain Disorders Research](#) 6 November 2020
- [Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#) 12 November 2020
- [Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#) D43 13 November 2020
- [Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#) 18 November 2020
- [Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries D43](#) 24 June 2021

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunities

### 1. Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine Strain Selection (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-055](#)

**Type:** R01

**Application Due Date:** February 11, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve understanding of the evolutionary dynamics of seasonal influenza to increase our capacity to predict the emergence of new antigenic variants and more accurately select strains for use in the seasonal influenza vaccine.

**Budget:** NIAID intends to commit \$4 million in FY 2022 to fund up to 6 awards. Application budgets are limited to \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 2. Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-20-046](#)

**Type:** R01

**Application Due Date:** Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castlemann disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection.

**Budget:** NCI intends to commit \$3,000,000 in each of two fiscal years 2021 and 2022 to fund an estimate of four to six awards each year. Future year amounts will depend on annual appropriations. Application budgets should reflect the actual needs of the proposed project. Application budgets may not exceed \$500,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 3. BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-20-620](#)

**Type:** F32

**Application Due Date:** December 9, 2020; August 10, 2021, April 11, 2022, December 9, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

**Budget:** The BRAIN Initiative intends to commit up to \$1.5 M per year in fiscal years 2021-2023 to fund an estimate of 20 awards per year. Individuals may receive up to 5 years of aggregate Kirschstein-NRSA support at the Award budgets are composed of stipends, tuition and fees, and institutional allowance. Individuals may receive up to 5 years of aggregate Kirschstein-NRSA support at the predoctoral level (up to 6 years for dual degree training, e.g., MD/PhD), and up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants (e.g., T32) and an individual fellowship award.

### 4. Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-20-701](#)

**Type:** R01

**Application Due Date:** January 8, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged but not required. [RFA-MH-20-701](#) uses the R01 grant mechanism while [RFA-MH-20-702](#) uses the R21 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism, while applicants with preliminary data may wish to apply using the R01 mechanism.

**Budget:** NIMH intends to commit an estimate of \$2,000,000 (Total Costs) in FY 2021 to fund 3-5 awards. NIDA intends to commit approximately \$1,500,000 (Total Costs) in FY 2021 to fund 2-3 awards. NINDS intends to commit approximately \$1,500,000 (Total Costs) in FY 2021 to fund 2-3 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: [Christa](mailto:Christa)  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: [Lizel](mailto:Lizel)  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105